Emyria Expands Authorised Prescribers for MDMA-Assisted Therapy

Emyria Ltd (ASX: EMD) expands its team of authorised prescribers with the addition of its first female specialist approved for MDMA-assisted therapy for Post-Traumatic Stress Disorder (PTSD).

This new psychiatrist joins Emyria after receiving Authorised Prescriber (AP) status from the Therapeutic Goods Administration (TGA).

This authorisation allows her to prescribe MDMA within a strict regulatory framework established by the TGA and according to an ethics committee-approved care model developed by Emyria.

A much-needed advancement for women’s mental health

The appointment is significant as women are nearly twice as likely to experience PTSD compared to men, with an estimated one million Australians affected. Emyria’s commitment to expanding treatment options aligns with this critical need.

Expanding capacity and building a unique approach

This authorisation not only increases Emyria’s capacity for patient care and clinical trials but also complements the company’s ongoing clinical facility expansion. Emyria’s focus is on developing and delivering innovative treatments for mental health and select neurological conditions through a unique model that integrates direct clinical services with drug development.

Dr. Michael Winlo, CEO of Emyria, commented:

“We are building a groundbreaking company that directly helps patients today while leveraging revenue and data insights to fuel long-term innovation.”

With up to a third of patients not responding effectively to traditional therapies, there’s a clear demand for more effective treatments. Emyria is actively addressing this need through:

  • EMDMA-001: An ethics-approved clinical trial evaluating MDMA-assisted therapy for PTSD.
  • Partnership with Reach Wellness: A binding research agreement to evaluate the treatment for first responders with PTSD. Subject to fundraising, Reach will subsidize treatment for an initial 50 qualified participants, with the first already enrolled.

A scalable commercialisation strategy

The addition of authorised prescribers strengthens Emyria’s efforts to provide more capacity for trials, patient care, and service revenue generation. The company’s commercialisation strategy involves:

  • Licensing its model: Partnering with mental health care providers across Australia to leverage Emyria’s unique capabilities.
  • Engaging with health payers: Improving access to these new treatments for patients who may benefit.

Emyria’s dedication to improving mental healthcare continues with this strategic expansion and innovative approach.

Articles of Interest